NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
Mayo Clinic
University of Aarhus
Dana-Farber Cancer Institute
Nova Scotia Health Authority
University Hospitals Cleveland Medical Center
Amsterdam UMC, location VUmc
Massachusetts Eye and Ear Infirmary
Genta Incorporated